{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:23Z","timestamp":1792979903168,"version":"4.5.0"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Songklanagarind Hospital Foundation"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec>\n<jats:title>Introduction<\/jats:title>\n<jats:p>Tenofovir alafenamide (TAF) is recommended for chronic hepatitis B (CHB) treatment in international guidelines according to its efficacy and safety. However, in phase III study, an increased LDL-c was observed in those who were switched from Tenofovir disoproxil fumarate (TDF) to TAF. Limited data exists on whether lipid profiles change only in individuals who switched to TAF from TDF or from any nucleoside\/nucleotide analogues (NUC). We investigated how switching to TAF affected lipid and cardiovascular outcomes in Thai CHB patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and methods<\/jats:title>\n<jats:p>We conducted a prospective observational study including CHB patients who had to switch from their prior NUC to TAF according to the national reimbursement policy in late 2022. All enrolled patients had lipid tests and transient elastography (TE) done at 0 and 48-week post-switch to TAF. Demographic data, prior NUC, liver biochemistry, controlled attenuated parameter (CAP) and liver stiffness (elastic modulus; E) data measured by TE were collected. The changes in lipid, Thai cardiovascular (CV) risk score, and TE results between 0 and 48-week were compared.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 110 patients who were switched to TAF and completed 48-week follow-up were analyzed. The prior NUCs were as follows: 47 Lamivudine (LAM), 22 Entecavir (ETV), and 41 TDF-based. Baseline characteristics were similar between the three groups except for underlying hypertension was more frequent and baseline total cholesterol was lower in the TDF-based group. At 48-week post-switch, the median LDL-c changes were -2.45, -5.9 and +8.8\u2009mg\/dL (p&lt;0.001), and total cholesterol changes were -4.5, -4 and +17\u2009mg\/dL (p&lt;0.001), in the ETV, LAM, and TDF-based group, respectively. Whereas the changes in hepatic steatosis (measured by CAP), and liver stiffness (measured by E) as well as Thai CV risk score were not significantly different. No cardiovascular events occurred during follow-up.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Significant increase in LDL-c and total cholesterol after switching to TAF were observed only in patients with prior TDF, but not in those with prior ETV or LAM. Careful monitoring of lipids after the switch may not be universally needed. Data regarding long-term cardiovascular outcomes are warrant.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0324897","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T18:10:42Z","timestamp":1748369442000},"page":"e0324897","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of switching from prior Nucleos(t)ide Analogue(s) to Tenofovir alafenamide on lipid profile and cardiovascular risk in patients with Chronic Hepatitis B"],"prefix":"10.1371","volume":"20","author":[{"given":"Witchayaporn","family":"Praguylertluck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apichat","family":"Kaewdech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naichaya","family":"Chamroonkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerha","family":"Piratvisuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0007-8214","authenticated-orcid":true,"given":"Pimsiri","family":"Sripongpun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"12","key":"pone.0324897.ref001","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/s41575-024-00967-4","article-title":"Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions","volume":"21","author":"L-Y Mak","year":"2024","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"pone.0324897.ref002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"EAftSotLEa, Liver EAftSot","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0324897.ref003","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"NA Terrault","year":"2018","journal-title":"Hepatology"},{"key":"pone.0324897.ref004","article-title":"Two-year efficacy of the real world roadmap concept for lamivudine therapy in chronic hepatitis B patients at Songklanagarind Hospital","volume":"101","author":"P Sripongpun","year":"2018","journal-title":"J Med Assoc Thai"},{"issue":"8","key":"pone.0324897.ref005","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.cgh.2007.05.004","article-title":"Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B","volume":"5","author":"EB Keeffe","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"pone.0324897.ref006","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S2468-1253(16)30024-3","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a\u00a0randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"HLY Chan","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"pone.0324897.ref007","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S2468-1253(16)30107-8","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"1","author":"M Buti","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"pone.0324897.ref008","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","article-title":"96\u00a0weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection","volume":"68","author":"K Agarwal","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0324897.ref009","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0261760","article-title":"Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B","volume":"17","author":"K Suzuki","year":"2022","journal-title":"PLoS One"},{"issue":"4","key":"pone.0324897.ref010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1111\/apt.17107","article-title":"Switching to tenofovir alafenamide for nucleos(t)ide analogue-experienced patients with chronic hepatitis B: week 144 results from a real-world, multi-centre cohort study","volume":"56","author":"E Ogawa","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"pone.0324897.ref011","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3350\/cmh.2021.0314","article-title":"Tenofovir alafenamide treatment may not worsen the lipid profile of chronic hepatitis B patients: a propensity score-matched analysis","volume":"28","author":"J Jeong","year":"2022","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"pone.0324897.ref012","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/ije\/dyq218","article-title":"Cohort profile: the electricity generating authority of Thailand study","volume":"41","author":"P Vathesatogkit","year":"2012","journal-title":"Int J Epidemiol"},{"issue":"1","key":"pone.0324897.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"SK Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"3","key":"pone.0324897.ref014","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jhep.2022.12.007","article-title":"Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis","volume":"78","author":"W-M Choi","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"pone.0324897.ref015","doi-asserted-by":"crossref","first-page":"758","DOI":"10.7326\/M20-4853","article-title":"Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV\u00a0: A Cohort Study","volume":"174","author":"B Surial","year":"2021","journal-title":"Ann Intern Med"},{"issue":"5","key":"pone.0324897.ref016","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/S2468-1253(19)30421-2","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study","volume":"5","author":"P Lampertico","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"pone.0324897.ref017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2468-1253(19)30450-9","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide: perhaps not as simple as we thought","volume":"5","author":"L-Y Mak","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"pone.0324897.ref018","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3350\/cmh.2024.0115","article-title":"Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer","volume":"30","author":"P-N Cheng","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"6","key":"pone.0324897.ref019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0270458","article-title":"HBV seroprevalence and liver fibrosis status among population born before national immunization in Southern Thailand: Findings from a health check-up program","volume":"17","author":"S Sono","year":"2022","journal-title":"PLoS One"},{"key":"pone.0324897.ref020","doi-asserted-by":"crossref","first-page":"1481051","DOI":"10.3389\/fmed.2024.1481051","article-title":"Effect of fatty liver disease on liver function and fibrosis in patients with chronic hepatitis B: a cross-sectional study","volume":"11","author":"X Fang","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"pone.0324897.ref021","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/liv.13271","article-title":"The prevalence of steatohepatitis in chronic hepatitis B patients and its impact on disease severity and treatment response","volume":"37","author":"P Charatcharoenwitthaya","year":"2017","journal-title":"Liver Int"},{"key":"pone.0324897.ref022","article-title":"Coexisting steatotic liver disease is not associated with long-term liver-related events in patients with chronic hepatitis B","volume":"13","author":"N Uman","year":"2025","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"2","key":"pone.0324897.ref023","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/apt.17765","article-title":"Body weight increase and metabolic derangements after tenofovir disoproxil fumarate switch to tenofovir alafenamide in patients with chronic hepatitis B","volume":"59","author":"P-N Cheng","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"pone.0324897.ref024","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s00535-020-01750-3","article-title":"Tenofovir-disoproxil-fumarate modulates lipid metabolism via hepatic CD36\/PPAR-alpha activation in hepatitis B virus infection","volume":"56","author":"K Suzuki","year":"2021","journal-title":"J Gastroenterol"},{"issue":"6","key":"pone.0324897.ref025","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/apt.14218","article-title":"Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers","volume":"46","author":"AA Shaheen","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"pone.0324897.ref026","doi-asserted-by":"crossref","first-page":"5465","DOI":"10.1002\/jmv.27977","article-title":"Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose, and uric acid in chronic hepatitis B patients","volume":"94","author":"Q Zhang","year":"2022","journal-title":"J Med Virol"},{"issue":"1","key":"pone.0324897.ref027","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3350\/cmh.2023.0328","article-title":"Cardiovascular risk in chronic hepatitis B patients treated with tenofovir disoproxil fumarate or tenofovir alafenamide","volume":"30","author":"H Hong","year":"2024","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"pone.0324897.ref028","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.cgh.2020.11.047","article-title":"Tenofovir alafenamide attenuates effects of diabetes and body mass on serum alanine aminotransferase activities in patients with chronic hepatitis B","volume":"20","author":"P Sripongpun","year":"2022","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T18:10:49Z","timestamp":1748369449000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324897"}},"subtitle":[],"editor":[{"given":"Tyng-Yuan","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324897","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}